The human microbiome refers to the trillions of microorganisms, including bacteria, fungi, and viruses, that inhabit different sites in the human body. These microbes play a vital role in maintaining human health and metabolism through diverse mechanisms such as regulating the immune system, aiding nutrient absorption, producing vitamins, and defending against pathogenic microbes. The growing applications of human microbiomes in disease diagnosis, treatments, drug development, and nutrition are driving significant attention towards exploring the human microbiome. Advances in sequencing technologies have enabled comprehensive profiling of microbial communities across the human body, revealing associations between compositional changes in the microbiome and various diseases. This is fueling research into microbiome-based diagnostics and therapeutics targeting a wide range of conditions like diabetes, obesity, neurological disorders, cancer, and infectious diseases. Additionally, the role of gut microbiota in energy harvesting and modulation of systemic inflammation and immunity links the microbiome to metabolic health. Studies indicate restoring microbial balance through probiotics or fecal microbiota transplant (FMT) can impact clinical outcomes of various diseases.
The global Human Microbiome Market is estimated to be valued at US$ 332 million in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023-2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends in the human microbiome market is the development of next-generation probiotics and postbiotics. Traditional probiotic applications have focused on generic bacterial strains. However, advances in microbiome research have enabled targeted design of synthetic and engineered probiotics tailored for specific health applications and disease conditions. Researchers are working on engineering probiotic bacterial species to promote colonization in the gut, precisely modulate immune responses, and secrete bioactive compounds. Postbiotics, the byproducts of beneficial bacteria, are also gaining attention due to their ability to convey health effects without live microbes. Developing stable, efficacious, and safe next-gen probiotics and postbiotics customized for unique human sub-groups holds promise to expand the therapeutic potential of microbiome-based interventions.
Porter’s Analysis
Threat of new entrants: Low due to established presence of major players and significant capital requirement for research and development.
Bargaining power of buyers: Moderate due to availability of alternate therapy options.
Bargaining power of suppliers: Moderate due to availability of substitute products.
Threat of new substitutes: Low as microbiome-based therapeutics offer novel treatment opportunities.
Competitive rivalry: High due to intense competition among existing players to gain major market share.
Key Takeaways
The Global Human Microbiome Market Size is expected to witness high growth. Advancements in sequencing technologies and bioinformatics are supporting research on the role of microbiome in human health.
Regional analysis comprises the North American region has the highest market share due to increasing funding from government and private organizations for research activities related to human microbiome. The Asia Pacific is expected to witness fastest growth rate owing to rising geriatric population, increasing awareness and developing healthcare infrastructure.
Key players operating in the human microbiome market are Enterome Bioscience, Seres Therapeutics, Vedanta Biosciences, Osel, ViThera Pharmaceuticals, Second Genome and others. Major players are focusing on partnerships and acquisitions to strengthen their product pipeline and market presence.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it